Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8

Benzinga · 3d ago
Leerink Partners analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and raises the price target from $5 to $8.